Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study (PASS DiabCancer)First published 16/12/2016 Last updated 16/01/2025 EU PAS number: EUPAS16424StudyOngoing